Brought to you by 
Ten investors take part in Foundation Medicine's $42.5mm Series B round; money added
15 Dec 2015
Executive Summary
A year after capping off its Series A round at $33.5mm, Foundation Medicine Inc. (developed the FoundationOne genome analysis profiling system for personalized cancer treatment decision-making) has brought in an impressive $42.5mm through its Series B round. Returning investors Third Rock Ventures, Google Ventures, and Kleiner Perkins Caufield & Byers were joined by new buyers Deerfield Management, Casdin Capital, Redmile Group, Roche Venture Fund, and WuXi Corporate Venture Fund. Two undisclosed backers (a fund and a strategic investor) also participated.
Deal Industry
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ten investors take part in Foundation Medicine's $42.5mm Series B round; money added
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice